Max CMD Abhay Soi is new president of NATHEALTH
New leadership team announced at NATHEALTH Annual General Meeting 2024
New leadership team announced at NATHEALTH Annual General Meeting 2024
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
This acquisition enables MTD to open new, strategic markets
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Subscribe To Our Newsletter & Stay Updated